Literature DB >> 31226502

Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy.

Anca M Segall1, Dwayne R Roach2, Steffanie A Strathdee3.   

Abstract

Increasingly, clinical infections are becoming recalcitrant or completely resistant to antibiotics treatment and multidrug resistance is rising alarmingly. Patients suffering from infections that used to be treated successfully by antibiotic regimens are running out of the treatment options. Bacteriophage (phage) therapy, long practiced in parts of Eastern Europe and the states of the former Soviet Union, is now being reevaluated as a treatment option complementary to and synergistic with antibiotic treatments. We discuss some current studies that have addressed synergistic killing activity between phages and antibiotics, the issues of treatment order and antibiotic class, and point to considerations that will have to be addressed by future studies. Overall, co-treatments with phages and antibiotics promise to extend the utility of antibiotics in current use. Nevertheless, a lot of work, both basic and clinical, remains to be done before such co-treatments become routine options in the hospital setting.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31226502     DOI: 10.1016/j.mib.2019.03.005

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  34 in total

1.  Standardized bacteriophage purification for personalized phage therapy.

Authors:  Tiffany Luong; Ann-Charlott Salabarria; Robert A Edwards; Dwayne R Roach
Journal:  Nat Protoc       Date:  2020-07-24       Impact factor: 13.491

Review 2.  Biological foundations of successful bacteriophage therapy.

Authors:  Carola Venturini; Aleksandra Petrovic Fabijan; Alicia Fajardo Lubian; Stefanie Barbirz; Jonathan Iredell
Journal:  EMBO Mol Med       Date:  2022-05-27       Impact factor: 14.260

3.  Nanoparticles Influence Lytic Phage T4-like Performance In Vitro.

Authors:  Xymena Stachurska; Krzysztof Cendrowski; Kamila Pachnowska; Agnieszka Piegat; Ewa Mijowska; Paweł Nawrotek
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

4.  Decoding the molecular properties of mycobacteriophage D29 Holin provides insights into Holin engineering.

Authors:  Varun Rakeshbhai Bavda; Aditi Yadav; Vikas Jain
Journal:  J Virol       Date:  2021-02-24       Impact factor: 5.103

Review 5.  Bacteriophage Therapy for Critical and High-Priority Antibiotic-Resistant Bacteria and Phage Cocktail-Antibiotic Formulation Perspective.

Authors:  Gursneh Kaur; Ritika Agarwal; Rakesh Kumar Sharma
Journal:  Food Environ Virol       Date:  2021-06-12       Impact factor: 2.778

6.  Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model.

Authors:  Yu Lin; Diana Quan; Rachel Yoon Kyung Chang; Michael Y T Chow; Yuncheng Wang; Mengyu Li; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2020-11-27       Impact factor: 5.571

7.  Antibiotics Act with vB_AbaP_AGC01 Phage against Acinetobacter baumannii in Human Heat-Inactivated Plasma Blood and Galleria mellonella Models.

Authors:  Bartłomiej Grygorcewicz; Marta Roszak; Piotr Golec; Daria Śleboda-Taront; Natalia Łubowska; Martyna Górska; Joanna Jursa-Kulesza; Rafał Rakoczy; Bartosz Wojciuk; Barbara Dołęgowska
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

Review 8.  The global preclinical antibacterial pipeline.

Authors:  Ursula Theuretzbacher; Kevin Outterson; Aleks Engel; Anders Karlén
Journal:  Nat Rev Microbiol       Date:  2019-11-19       Impact factor: 60.633

9.  Phage Resistance in Multidrug-Resistant Klebsiella pneumoniae ST258 Evolves via Diverse Mutations That Culminate in Impaired Adsorption.

Authors:  Shayla Hesse; Manoj Rajaure; Erin Wall; Joy Johnson; Valery Bliskovsky; Susan Gottesman; Sankar Adhya
Journal:  mBio       Date:  2020-01-28       Impact factor: 7.867

10.  Bacteriophages Combined With Subtherapeutic Doses of Flucloxacillin Act Synergistically Against Staphylococcus aureus Experimental Infective Endocarditis.

Authors:  Jonathan Save; Yok-Ai Que; José M Entenza; Camille Kolenda; Frédéric Laurent; Grégory Resch
Journal:  J Am Heart Assoc       Date:  2022-01-19       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.